The study was aimed at finding what factors in evoked potentials and EEG related to stuttering in subjects 6–25 years of age. Thirty-seven subjects who stuttered and 25 nonstuttering subjects, matched for age, sex and education, were evaluated employing visual evoked potentials, auditory evoked potentials, event-related potentials (P300), WISC-(IQ), and electroencephalography. A significant reduction of amplitude of P100 of visual evoked potentials was found in stutterers with a significant prolongation of wave latencies I, III, V and interpeak latencies I–III and I–V in brainstem auditory evoked potentials. No significant abnormalities were recorded in P200, N200 and P300 of event-related potentials in stutterers compared with the control group. The dominant EEG rhythm was slower in stutterers with a significant interhemispheric asymmetry compared with the control group. Fifty-four percent of the stutterers had pathological EEG. Epileptiform activities were recorded in 16.2% of stuttering subjects. Focal left temporal spike activity was recorded in 5.4% of stuttering subjects. The findings of this study point to a possible role of an organic etiopathogenesis of stuttering.

This content is only available via PDF.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.